Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01703169

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The investigators hypothesis is that eltrombopag given to patients with moderate to very severe aplastic anemia will result in an increase in platelet counts. The investigators hypothesize that in patients with moderate to very severe aplastic anemia, treatment with eltrombopag will lead to fewer platelet transfusions, red blood cell transfusions, and fewer bleeding events. The investigators hypothesize that in patients with moderate to very severe aplastic anemia, eltrombopag will have an acceptable toxicity rate <3%, at doses that result in increased platelet counts. Finally the investigators hypothesize that plasma eltrombopag levels in peripheral blood will correlate with improved platelet counts.

Status: 
Recruiting
Study Date: 
Thu, 09/27/2012 to Tue, 11/01/2016
Bone Marrow Disease(s): 
aplastic anemia
Associated Drug(s): 
Intervention: 
Drug: Eltrombopag Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count